Cargando…

Definition of Castrate Resistant Prostate Cancer: New Insights

The term castrate resistant prostate cancer (CRPC) was initially proposed by the Prostate Cancer Working Group 2 in 2008 to define the state of clinical and/or biochemical progression of prostate cancer (PCa) in an environment with very low serum testosterone concentration. Clinical progression is b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morote, Juan, Aguilar, Adriana, Planas, Jacques, Trilla, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945091/ https://www.ncbi.nlm.nih.gov/pubmed/35327491 http://dx.doi.org/10.3390/biomedicines10030689

Ejemplares similares

Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review
por: Aguilar, Adriana, et al.
Publicado: (2023)

Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration
por: Morote, Juan, et al.
Publicado: (2020)

Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
por: Triquell, Marina, et al.
Publicado: (2022)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
por: Cánovas, Verónica, et al.
Publicado: (2017)

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
por: Morote, Juan, et al.
Publicado: (2017)

Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review
por: Cuadras, Mercè, et al.
Publicado: (2022)

Multiparametric MRI for Staging of Prostate Cancer: A Multicentric Analysis of Predictive Factors to Improve Identification of Extracapsular Extension before Radical Prostatectomy
por: Triquell, Marina, et al.
Publicado: (2022)

The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category
por: Morote, Juan, et al.
Publicado: (2022)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2023)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand
por: Morote, Juan, et al.
Publicado: (2022)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category
por: Morote, Juan, et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer
por: Morote, Juan, et al.
Publicado: (2022)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
por: Acar, Ömer, et al.
Publicado: (2013)

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
por: Campistol, Miriam, et al.
Publicado: (2022)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Integrated network model provides new insights into castration-resistant prostate cancer
por: Hu, Yanling, et al.
Publicado: (2015)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

A Systematic Review of the Current Status of Magnetic Resonance–Ultrasound Images Fusion Software Platforms for Transperineal Prostate Biopsies
por: Paesano, Nahuel, et al.
Publicado: (2023)

Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs
por: Ferretti, Simone, et al.
Publicado: (2023)

The True Utility of Predictive Models Based on Magnetic Resonance Imaging in Selecting Candidates for Prostate Biopsy
por: Morote, Juan, et al.
Publicado: (2022)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand
por: Lojanapiwat, Bannakij, et al.
Publicado: (2017)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease
por: Wang, Bo-Ren, et al.
Publicado: (2022)

New immunotherapeutic paradigms for castration-resistant prostate cancer
por: Galluzzi, Lorenzo
Publicado: (2013)

New ideas in preventing castration-resistant prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2017)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Castration-resistant prostate cancer: systemic therapy in 2012
por: Maluf, Fernando C., et al.
Publicado: (2012)

Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Molecular and cellular mechanisms of castration resistant prostate cancer
por: Huang, Yiqiao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d1hbc7j55m1ve07upldeu2t04h